Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.

NCT01254136 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01254136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01254136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
October 31, 2010
Completion date
October 31, 2011
Enrollment
20 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer